Pharmerica (PMC) Tops Q4 EPS by 7c

Pharmerica (NYSE: PMC) reported Q4 Adj. EPS of $0.58, $0.07 better than the analyst estimate of $0.51. Revenue for the quarter came in at $534.4 million versus the consensus estimate of $525.22 million.

GUIDANCE:

Pharmerica sees FY2017 Adj. EPS of $1.75-$1.95, versus the consensus of $2.18. Pharmerica sees FY2017 revenue of $2.3-2.4 million, versus the consensus of $2.24 million.

For earnings history and earnings-related data on Pharmerica (PMC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• SanDisk upgraded at JPMorgan after investor day; shares climb